Third Annual International Meeting

Theme:
“Outcomes Research: Meeting the Needs of Health Care Decision Makers

May 27 – 30, 1998, Philadelphia Marriott
Philadelphia, Pennsylvania

For more information contact ISPOR
20 Nassau Street, Suite 307
Princeton, NJ 08542
Phone: 609-252-1305 • Fax: 609-252-1306
email: econhealth@aol.com

Features
• GENERAL SESSIONS
• CONTRIBUTED PAPERS
• CONTRIBUTED WORKSHOPS
• EXHIBITS
• PERSONNEL PLACEMENT CENTER
• SHORT COURSES

ISPOR: Uniting Science and Practice
The International Society for Pharmacoeconomics and Outcomes Research is a non-profit international organization promoting the science and practice of pharmacoeconomics and health outcomes research. The International Society represents researchers and practitioners including pharmacists, physicians, economists, and other professionals involved in pharmacoeconomic analysis and health outcomes assessment.

Planning Committee

Program Chair
Newell E. McElwee PharmD, MSPH • Schering Plough Integrated Therapeutics Group, Inc.

General Sessions Chair
Bryan R. Luce PhD, MBA • MEDTAP International

General Sessions Committee
Marc L. Berger MD • Merck & Co.
Lorne Basskin PharmD • Butler University
Jon Clause RPh, MS • United Healthcare Corp.
Jonathan Cooke M Pharm, PhD • Merck & Co.
Frederick K. Orkin MD • Dartmouth Medical School
Mary Kaye Willian DrPH • Astra Merck

Contributed Papers Review Co-chair
Renée J Goldberg Arnold PharmD • Pharmacon International, Inc.
Eva Lydick PhD • SmithKline Beecham

Contributed Papers Review Committee
Thomas A. Abbott III PhD • Merck & Co.
Mohan Bala PhD • Centecor Inc.
Rami Ben-Joseph PhD • Merck & Co.
Robert M. DeMarinis PhD • Smith Kline Beecham
Jean Lee Gillispie • National Pharmaceutical Council
Z. Thomas Grapes PhD • Mercer University
Jana R. Grippi M PharmBA • Roche Laboratories, Inc.
Barbara Edelman Lewis PhD • Collaborative Clinical Research Inc.
Frederick K. Orkin MD • Dartmouth Medical School
Paula Funk Orsini PhD • PAREXEL/ S&FA
Paula Paradise MS, MBA • IMS America
Karen L. Rascati PhD • University of Texas
Jonathan Selzter MBA, MD • Premier Research Worldwide
Marilyn Dix Smith Ph.D. • International Society for Pharmacoeconomics and Outcomes Research
Paul Stang PhD
Todd Wandstrat PharmD • West Virginia University
Barbara Yawn M.D. • O Imstead Medical Center
Terri Young PhD • Glaxo-Wellcome Inc.
Winnie Yu PharmD • University of Pittsburgh, School of Pharmacy

Contributed Workshop Review Committee
Rami Ben-Joseph PhD • Merck & Co.
Kim Allen Heithoff • Schering Plough Integrated Therapeutics Group, Inc.
Newell E. McElwee PharmD, MSPH • Schering Plough Integrated Therapeutics Group, Inc.

CPE Coordinator
Lorne Basskin PharmD • Butler University

Podium Session Coordinator
Susan T. Sacks PhD Roche Laboratories
Third Annual International Meeting
International Society for Pharmacoeconomics and Outcomes Research

Schedule

Wednesday, May 27

8 - 5 PM
Registration

10 - 5 PM
Personnel Placement

1 - 1:15 PM
Welcome
James Smeeding RPh, MBA, Director, Center for Pharmacoeconomics Studies, University of Texas, College of Pharmacy, ISPOR President

1 - 3 PM
First General Session:
“Are the Current Methodology and Dissemination Information Techniques Useful for Health Care Decision-makers?”
Moderator: Donald Young MD, Vice President, American Association of Health Plans
Keynote Speaker: David Banta MD, MPH, Senior Researcher, Netherlands Organization for Applied Scientific Research
Keynote Address: “The Usefulness of Current Methods and Dissemination Techniques for Public Policy Decisions”
“Decision-analytic Approach: Useful Tool or Absolute Necessity in Informing Health Care Decision-making”
John Hutton, Vice President of European Operations, MEDTAP International
“Research on Drug Effectiveness (or is it Efficacy?)”
Stuart C. Hartz ScD, President, Medical Research International
Mark Zitter MBA, Chief Executive Officer, The Zitter Group

3:30 - 5 PM
Contributed Podium Presentations
“ECONOMIC AND OUTCOMES ISSUES IN MENTAL HEALTH”
THE ECONOMIC BURDEN OF ALZHEIMER’S DISEASE TO MEDICAID IN CALIFORNIA (“MEDI-CAL”)
Menzin J, Lang K, Friedman M, Neumann P, Boston Health Economics, Inc., Billerica, MA; Harvard School of Public Health, MA USA
COST IMPACT OF USING OLANZAPINE AT A VETERANS AFFAIRS MEDICAL CENTER
Weiss MA, McCollum M. Department of Veterans Affairs Medical Center, Denver CO, USA
COMPARISON OF SUMATRIPTAN (IMITREX®) AND OVER-THE-COUNTER (OTC) MEDICATION USE ACCORDING TO MIGRAINE SEVERITY
Yuran T, Schaffer M, Lofland JH, Johnson NE, Johnson KA. Thomas Jefferson University, Philadelphia, PA, USA; HealthAmerica of Pennsylvania Inc., Pittsburgh, PA, USA
SSRI ANTIDEPRESSANT USE PATTERN AND THEIR RELATION TO CLINICAL GLOBAL IMPRESSION (CGI) NATURALISTIC STUDY
Hylan TR, Meneades L, Crown WH, Sacristan JA, Gilaberte I, Montejo AL. Eli Lilly and Company, Indianapolis, IN USA; Hospital Universitario, Salamanca, Spain; The MEDSTAT Group, Cambridge, MA USA
SSRI ANTIDEPRESSANT USE IN PRIMARY CARE IN THE UNITED KINGDOM: A MULTIVARIATE ANALYSIS
Hylan TR, Donoghue JM, Dunn RL, Ozminkowski RJ. Eli Lilly and Company, Indianapolis, IN USA; Wirral Hospital, Merseyside, UK; The MEDSTAT Group, Ann Arbor, MI, USA
EVALUATION OF ANTIDEPRESSANT UTILIZATION PATTERNS AND ASSOCIATED DEPRESSION DIAGNOSIS AMONG PATIENTS IN A NATIONAL MANAGED CARE ORGANIZATION
Way K, Brintnell EO, Whiteman DJ, Young CH, Gregor K. Hughes T, PCS Health Systems, Inc., Scottsdale, AZ; HCC Behavioral Care, Eden Prairie, MN USA
Third Annual International Meeting
International Society for Pharmacoeconomics and Outcomes Research

Schedule

“ECONOMIC AND OUTCOMES ISSUES IN CARDIOVASCULAR DISEASE”
ECONOMIC OUTCOMES OF CAROTID ENDARTERECTOMY FOR STROKE
Patterson HK1 and Seltzer J2, 1SmithKline Beecham Pharmaceuticals, Collegeville, PA, USA, 2Premier Research Worldwide, Philadelphia, PA, USA

COST-EFFECTIVENESS AND ECONOMIC EFFICIENCY: THE CASE OF STATIN THERAPY IN SECONDARY PREVENTION OF CORONARY HEART DISEASE
Russell MW, Huse DM, Miller JD, Hartz SC, Medical Research International, Burlington, MA, USA

ADHERENCE TO HYPERTENSION THERAPY: THE EFFECT OF INITIAL DRUG CHOICE
Caro JJ1, Speckman JL1, Salas M1, Raggio G1, Jackson JD2. 1Caro Research, Boston, MA, 2Bristol-Myers Squibb, Princeton, NJ, USA

COST-EFFECTIVENESS OF A PHARMACOLOGICAL APPROACH TO RESTENOSIS PROPHYLAXIS
Schömig A1, Schwicker D2, Darcis T3, Banz K4, Serruys PW5. 1Universität München, München, Germany; 2PARPEX International, Alexandria VA, USA; 3UCB Pharm SA, Belgium; 4Health Econ Ltd Basle, Switzerland; 5University Rotterdam, Rotterdam, The Netherlands

EFFECT OF COMPLIANCE ON HEALTH AND ECONOMIC OUTCOMES: ROLE OF CONJUGATED ESTROGEN ON DEPRESSION AND CARDIOVASCULAR DISORDERS.
Heaton AH1, Flinner A1, Martin SL1, Emmett KE2, Buatti MC2; 1Pharmacy Gold, Eagan, MN, USA; 2Wyeth-Ayerst Laboratories, Philadelphia, PA, USA

CONFOUNDING BY INDICATION IN CALCIUM CHANNEL BLOCKER TREATMENT OF HYPERTENSION OR ANGINA
Mallick R1, Leader S1, Roht L2, 1Pracon, Reston, VA, USA; 2Hoechst Marion Roussel, Kansas City, MO, USA

5 - 6 PM Plenary Speaker and ISPOR Awards Presentation
Plenary Speaker: Robert Brook MD, ScD, Vice President, RAND Health Program
Plenary Presentation: “Health Outcomes Research: Past, Present, and Future”

6 - 7 PM ISPOR Opening Day Reception

8 - 5 PM Second General Session:
“The Role of Government in Outcomes Research”
Moderator: Louis Morris PhD, Senior Vice President, PPR Inc.
Keynote Speaker: John Eisenberg MD, MBA, Administrator, Agency for Health Care Policy and Research
Keynote Address: “The Role of Government in Outcomes Research”

“Update on the FDA Policy concerning the FDA Modernization Act of 1997”
Laurie B. Burke RPh, MPH, Epidemiologist, Food and Drug Administration

“Implementation Issues of the FDA Modernization Act of 1997”
William W. Vodra, Esquire, Arnold and Porter

Thursday, May 28

Graduate Education Opportunities

The ISPOR Third Annual International Meeting will provide opportunities to learn more about graduate or executive training programs in pharmacoeconomics, health economics, quality-of-life, outcomes research, or health policy.

If you would like to have a table-top display for materials about your graduate masters, doctoral, post-doctoral, or executive training program in pharmacoeconomics, health economics, quality-of-life, outcomes research, or health policy, call Jennifer Olson, ISPOR Director of Meetings and Conventions, at (609) 252-1305 or e-mail to econhealth@aol.com for information and application.
# Third Annual International Meeting

**International Society for Pharmacoconomics and Outcomes Research**

## Schedule

### 10:30 - 12 PM

**Contributed Podium Presentations**

**“ECONOMIC AND OUTCOMES ISSUES IN MENTAL HEALTH & NEUROLOGIC DISORDERS”**

TREATMENT CHOICE AND THE INCIDENCE AND ECONOMIC INTENSITY OF HOSPITAL IN PATIENT USE BY DEPRESSED PATIENTS

Croghan TW, Kneseler TJ, Melfi CA, Klein EG, Elf Lilly and Company, Indianapolis, IN, USA.

**MEDICAL COSTS OF EFFEXOR® VERSUS TRICYCLIC OR TETRACYCLIC ANTIDEPRESSANT THERAPY AFTER SWITCHING FROM SELECTIVE SEROTONIN REUPTAKE INHIBITORS**


**ECONOMIC AND OUTCOMES ISSUES IN MENTAL HEALTH & NEUROLOGIC DISORDERS**

MEDICAL COSTS OF EFFEXOR® VERSUS TRICYCLIC OR TETRACYCLIC ANTIDEPRESSANT THERAPY AFTER SWITCHING FROM SELECTIVE SEROTONIN REUPTAKE INHIBITORS


**“ECONOMIC AND OUTCOMES ISSUES IN CARDIOVASCULAR DISEASE”**

COST OF ITALIAN HYPERTENSIVE PATIENT: A FEASIBILITY STUDY FROM THE PANDORA PROJECT

Berto P, Degli Esposti E, Buda S, Sturani A, Reggio S, PBE consultants, Verona; 3SM delle Croci Hospital, Ravenna; 4Clicon Software, Ravenna; 5Pfizer Italiana, Roma, Italy

DEVELOPMENT AND CROSS-VALIDATION OF A COMORBIDITY INDEX FOR A STROKE POPULATION.

Ricci JF, Martin BC, College of Pharmacy, University of Georgia, Athens, GA, USA.

EVALUATION OF THE COSTS OF CORONARY HEART DISEASE IN BELGIUM

Annemans L, Curra W, Van Rompay W, University of Ghent, Belgium, Athens, GA, USA.

IN-HOSPITAL SURVIVAL AMONG PATIENTS WHO RECEIVED EITHER AMRINONE, DOBUTAMINE OR MILRINONE

Weycker DA, Simons WR, Department of Health Economics, Sanofi Pharmaceuticals, New York, NY, USA.

PREVENTING CARDIOVASCULAR DISEASE: IS PRIMARY PREVENTION WITH PRAVASTATIN WORTH THE MONEY?

Caro JJ, Payne K, Shepherd J, Pettitt D, WOSCOPS Economic Analysis Committee, Caro Research, Boston, MA, USA, Caro Research Montreal, Montreal, Canada, University of Glasgow, Glasgow, Scotland, Bristol-Myers Squibb, Princeton, NJ, USA.

TORSERMIDE AND FUROSEMIDE IN THE TREATMENT OF THE EDEMA OF HEART FAILURE: INTERIM RESULTS OF A RANDOMIZED EFFECTIVE ESSTRIAL.

Murray M, Strove K, Pierson W, Heyman E, Minick S, Tierney W, Boehringer-Mannheim Pharmaceuticals, Gaithersburg, MD, USA, Indiana University School of Medicine, Indianapolis, IN, USA.

### 1 - 3:15 PM

**Contributed Workshops (3 sessions @ 35 minutes)**

See – CONTRIBUTED WORKSHOP SECTION.
Third Annual International Meeting
International Society for Pharmacoeconomics and Outcomes Research

Schedule

3:30 - 5 PM

Third General Session:
“The Role of the Patient in Health Care Decision-making”
Moderator: Peter Ubel MD, Assistant Professor, University of Pennsylvania, Leonard Davis Institute
Keynote Speaker: Norman Daniels PhD, Professor of Medical Ethics, Tufts University
Keynote Address: “The Legitimacy of Limit Setting: Political and Patient Obstacles to the Use of Outcomes Research in Decision Making”

“Can Patient Centered Decision Making Yield Cost-Effective Care”
Robert Nease Jr. PhD, Assistant Professor, Washington University School of Medicine

“Health Care Decision Making: Its in the Consumers’ Hands”
Linda Gladner, Executive Director, National Consumers League

5 - 6 PM

ISPOR Business Meeting

6 - 7 PM

Exhibitors Open House and Reception

Friday, May 29

Registration

Personnel Placement

Exhibits and Contributed Poster Presentations in Exhibit Hall

Contributed Workshops (3 sessions @ 35 minutes)
See - CONTRIBUTED WORKSHOPS SECTION.

Contributed Podium Presentations

“ECONOMIC AND OUTCOMES ISSUES IN GI DISORDERS AND RENAL DISEASE”

ECONOMIC AND CLINICAL OUTCOMES MODELS FOR THE EVALUATION OF DRUG THERAPY
STRATEGIES IN TREATMENT OF GERD
McGhan WF1, Smith MD2, Crawley JA3, 1Philadelphia College of Pharmacy and Science, Philadelphia, PA, USA; 2Health Decision Strategies, Princeton, NJ, USA; 3Astra Merck Inc., Wayne, PA, USA

UPPER GASTROINTESTINAL SYMPTOMS AND NONCOMPLIANCE WITH DOSING IN STRUCTUR S
ASSOCIATED WITH ALENDRONATE FOR OSTEOPOROSIS IN A LARGE HMO
Ettinger B1, Schein JR2, Pressman A1, 1Division of Research, Kaiser Permanente Medical Care Program, Oakland, CA, USA; 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

COST-EFFECTIVENESS OF PROTON PUMP INHIBITORS IN GASTRIC ULCER
Ikeda S, Ikegami N, Keio University, School of Medicine, Tokyo, Japan.

PROSPECTIVE ECONOMIC EVALUATION IN A PHASE IIIb RENAL TRANSPLANT CLINICAL TRIAL
Arnold RJG1, Pettit KG1, Diecseraj j2, Fastenau j2, Kaniecki DJ1, 1Pharmaco International, Inc New York, NY, USA; 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

ACUTE EVARICABLE BLEEDING IN GASTROINTESTINAL SCleroTherapy AND SOMATOTRIN RESISTANCE
Weißflog D1, Sauer B1, Darcis T1, Schwicker D1, Staritz M1, 1HealthEcon, Basle, Switzerland, 2Hospital Villingen-Schwenningen, Germany, 3UCB Pharma, Brussels, Belgium, 4PAREXEL International, Alexandria, VA, USA

PREDICTORS OF DIAGNOSTIC RELATED GROUP DAY OUTLIERS IN THE MEDICARE END STAGE RENAL DISEASE POPULATION
Vilas-Boas I, Centro de Estudos de Farmacoeconomia, Associação Nacional de Farmacêuticos, Lisbon, Portugal

“ECONOMIC AND OUTCOMES ISSUES IN INFECTIOUS DISEASE”

RANDOMISED PROSPECTIVE STUDY COMPARING COST-EFFECTIVENESS OF TEICoplanin AND VANCOMYCIN AS SECOND-LINE EMPIRIC THERAPY FOR INFECTIOUS NEUTROPENIC PATIENTS
Domínguez-Gil A, Pérez M, Santos L, San Miguel J F, Vázquez L, Vilches P, Gutierrez N, García-Saiz R, Caballero D, Hospital Universitario de Salamanca, Salamanca, Spain
WILLINGNESS TO PAY FOR HIV PREVENTION: A STUDY OF HIGH AND LOW-RISK GROUPS.
Flanders S, Saint Louis University, School of Public Health, St. Louis, MO, USA.

PRESCRIBING PATTERNS FOR TREATMENT OF UPPER RESPIRATORY INFECTIONS
McLaughlin TP, Lalla DV and Kozma CM College of Pharmacy, The University of South Carolina, Columbia, SC, USA.

EVALUATION OF THE COST-EFFECTIVENESS OF MANAGEMENT STRATEGIES IN CYTOMEGALOVIRUS INFECTION AND DISEASE
Annemans L1, Mauskopf J2, Richter A3, Chulay J3, Macaline G1, 1HEDM, Belgium; 2Research Triangle Institute, RTP, N C, USA; 3G laxo Wellcome, RTP, N C, USA

SOCIO-ECONOMIC RELEVANCE OF PATIENT TREATMENT OF SKIN AND SOFT TISSUE INFECTIONS WITH TAZOBACTAM / PIPERACillin 0.5 g / 2.0 g IN COMPARISON WITH AMOXICILLIN / CLAVULANIC ACID, CEFTRIAXON, Enoxacin, CETOFAXIME
Bruchhausen Y, Rappenhner B, Institute of Empirical Health Economics, O denthal, Germany

CO ST-EFFECTIVENESS OF LIPO SO MAL DAUN O RUBIC IN VERSUS LIPO SO MAL DOX O RUBIC IN IN KAPO SI SARCO MA.
Egan, T1 Henry, H3 1Philadelphia College of Pharmacy and Science, Philadelphia, PA 2Graduate Hospital, Philadelphia, PA, USA

“METHODOLOGY AND GUIDELINE DEVELOPMENT ISSUES”

IMPROVING CLINICAL OUTCOMES BY INTEGRATING A NORMALIZED, STANDARDIZED, COMPARATIVE DATABASE INTO THE PROCESS OF CLINICAL QUALITY IMPROVEMENT.
Bryant D1, Mignardi W1, Seltzer J1, 1Premier, Inc., Charlotte, NC, USA, 2Premier Research Worldwide, Philadelphia, PA, USA

DISEASE MANAGEMENT IN HYPERTENSION: THE BENEFITS OF MEETING GUIDELINE GOALS FOR BLOOD PRESSURE
Huse DM1, Usry CA2, Hartz SC1, 1Medical Research International, Burlington, MA, USA, 2Astra Merck Inc., W ayn e, PA, USA.

A NEW PARADIGM FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE A SOCIAL-CLINICAL MODEL
W an Gj, Counte MA, Cell a DF. Merck & Co., Inc., West Point, PA, USA

A RETROSPECTIVE APPROACH TO EVALUATE QALY: ESTIMATION OF HEALTH UTILITY IN DEX FROM THE SF-36 IN A MANAGED CARE POPULATION
Sengupta N, Nichol M. University of Southern California, Los Angeles, CA, USA.

HEALTH UTILITIES IN DEX: FURTHER EVIDENCE OF RESPONSIVENESS
Torrance GW1,2, Feeny D1, Furlong W1, Barr RD1, DePauw S1, 1McMaster University, Hamilton, O ntario, Canada. 2Innovus Research Inc., Burlington, O ntario, Canada.

SURVEY STRATEGIES IN THE REVISION OF THE GUIDELINES FOR ECONOMIC EVALUATION: CANADA

Networking Opportunities

The ISPOR Third Annual International Meeting will provide networking opportunities for recipients, preceptors, and sponsors of Fellowships in Pharmacoeconomics and Outcomes Research. Look for the ISPOR Fellowship Center in Exhibit Hall.
Third Annual International Meeting
International Society for Pharmacoeconomics and Outcomes Research

Schedule

1:30 - 3 PM

Contributed Podium Presentations

“ECONOMIC AND OUTCOMES ISSUES IN CRITICAL CARE”
SOCIO-ECONOMIC EFFICIENCY OF PROPHYLAXIS OF EXACERBATIONSWITH N-ACETYLCYSTEINE IN PATIENTS WITH CHRONIC BRONCHITIS
Rappenhöner B, Bachinger A, Rychlik R. Institute of Empirical Health Economics, Odenthal, Germany

“STANDARDIZATION ISSUES IN EMERGENCY DEPARTMENT PATIENTS”
Dominguez-Gil A, Bajo O, Otero MJ, Garcia-Gutierrez JF, Hospital Universitario de Salamanca, Salamanca, Spain.

MODELING SIDE EFFECT COSTS FROM LITERATURE-BASED DATA: STEROID-INDUCED SIDE EFFECTS IN RENAL TRANSPLANTATION
Veenstra DL, Stergachis A, and Sullivan SD. University of Washington School of Pharmacy, Seattle, WA, USA.

INCREMENTAL COST-EFFECTIVENESS ANALYSIS COMPARING 4-LAYER BANDAGE SYSTEM WITH AND WITHOUT APLIGRAFT™ FOR THE OUTPATIENT TREATMENT OF VENOUS LEG ULCERS

COST-BENEFIT ANALYSIS OF RECOMBINANT ERYTHROPOIETIN IN PREMATURE NEONATES
Wandstrat TL, Maxwell SR. West Virginia University, Charleston, W.V, USA.

METHODOLOGY AND GUIDELINE DEVELOPMENT ISSUES
POOR ADHERENCE TO HYPERTENSION TREATMENT GUIDELINES: AN ANALYSIS OF THERAPEUTIC CHOICES
Huse DM, Roht LH, Hartz SC. Medical Research International, Burlington, MA, Hoechst Marion Roussel, Kansas City, MO, USA.

THE UTILIZATION AND COSTS OF PRESCRIPTION DRUGS IN A TEXAS MEDICAID MANAGED CARE PILOT PROGRAM
Johnsrud MT, Lawson KA. The University of Texas at Austin, Austin, TX, USA.

POSTMARKETING OUTCOMES STUDIES: BENEFITS AND RISKS
Garfield FB, Caro JJ, Caro Research, Boston, MA, USA.

RELATIONSHIP BETWEEN QUALITY OF LIFE, DISEASE SEVERITY AND PHYSICIAN VISITS IN MANGED CARE PATIENTS WITH ATOPIC DERMATITIS
Fagan Si, Frech F, Pettit KG, Bailey E, Kaniecki DJ. A. R. Brown RJG, Fivenson D. Henry Ford Hospital, Detroit, MI.

ADHERENCE OF HEALTH CARE WORKERS TO HEPATITIS B VACCINATION (HBV) POLICY IS INFLUENCED BY LEADERSHIP
Sutton EL. DoD Pharmacoeconomic Center, Fort Sam Houston, TX, USA.

FORMULARY IMPACT DECISION MODELING IN HMG- CO A REDUCTASE INHIBITORS
Corey R, Sung JCY, Novartis Pharmaceuticals Corp. East Hanover, N.J.

3 - 4:30 PM

Fourth General Session:

“ISPOR R Consensus Development Advisory Panel Reports”
Moderator: Jean Paul Gagnon PhD, Director

Developing Consensus on Pharmacoeconomic Methodology

Modeling Studies Advisory Panel Report – Chairs: Joseph Jackson PhD, Bristol-Myers Squibb & Joel Hay PhD, University of Southern California.

Developing Consensus on Pharmacoeconomic Education and a Code of Ethics

Developing Consensus on How to Communicate Pharmacoeconomic Results
Pharmacoeconomic Applications Advisory Panel Report – Chairs: Jon Clouse RPh, MS, United Health Care Corporation & Jean Paul Gagnon PhD, Hoechst Marion Roussel

Rapporteur
Hugh Tilson MD, PhD, Glaxo-Wellcome

Saturday, May 30

SHORT COURSES (am and pm sessions)
Pharmacoeconomics & Beyond - (am session)
Economic analyses and calculations including design of pharmacoeconomic studies will be presented. This course is designed for individuals with no prior experience with pharmacoeconomics. [IBM compatible computer with Windows 95 is recommended]

Advanced Pharmacoeconomics - (pm session)
Evaluations of pharmacoeconomic studies, sample size calculations, statistical testing will be presented. This course is designed for individuals with some experience with pharmacoeconomics.

Decision Analytic Modeling - Introduction - (am session)
Computer-assisted decision analytic modeling including design of decision trees and sensitivity analysis will be presented. This course is designed for individuals with no prior experience with decision analytic modeling. [IBM compatible computer with Windows 95 is required]

Decision Analytic Modeling - Advanced - (am & PM session)
Computer-assisted decision analytic modeling including design of design trees, sensitivity analysis, Markov, Bayesian, and run-time models will be presented. Prior experience recommended. [IBM compatible computer with Windows 95 is required]

Meta-analysis and Other Statistical Methods: Theory - (am session)
Analytical methods for assessing the quality of evidence for health care interventions will be discussed. This course is designed for individuals with no prior experience with meta-analysis.

Meta-analysis and Other Statistical Methods: Applications - (pm session)
Analytical methods for assessing the quality of evidence for health care interventions including applications of meta-analysis in pharmacoeconomic studies and health care decision-making will be discussed. This course is designed for individuals with prior experience with meta-analysis.

Quality-of Life Instruments & Outcomes Measures - (am session)
Health outcomes measurement instruments: conceptual and measurement models, reliability, validity, responsiveness, interpretability, respondent and administrative burden, alternate forms and cultural and language adaptation will be discussed.

Bayesian Analysis for Decision Making in Health Care - (am session)
Bayes theorem, clinical significance of true and false positive rates, odds ratio forms and relevance to health care decision making will be discussed. [IBM compatible computer with Windows 95 is recommended]
**Third Annual International Meeting**

*International Society for Pharmacoeconomics and Outcomes Research*

**Contributed Workshops**

**Session 1:** DM1; UT1; CM1; CM2; MM2; MM4; DA1; DA2; DA3  
**Session 2:** DM2; UT2; CM3; CM4; MM1; MM6; DA4; DA5; DA6  
**Session 3:** DM3; UT3; CM5; CM6; MM3; MM5; MM7; DA7; DA8

27 workshops are presented on Thursday and again on Friday. You have the opportunity to attend 6 of these 27 workshops over the two-day period. You can choose three (3) different workshops on Thursday (one from each of the three sessions given on Thursday), and three (3) workshops on Friday (one for each of the three sessions given on Friday.)

**Workshop Topics**

"MODELING METHODOLOGY ISSUES"

**MM1**  
**MONTE CARLO SIMULATION IN HEALTH CARE MODELS**  
Richter A, Mauskopf JA. Research Triangle Institute, Research Triangle Park, NC, USA

**MM2**  
**DESIGNING COMPUTER MODELS TO CONVEY COST-EFFECTIVENESS ANALYSES RESULTS**  
Parente ST, Gardner, EN, Mohr, P. Project HOPE Center for Health Affairs, Bethesda, MD, USA

**MM3**  
**DEVELOPMENT OF DRUG USE PERFORMANCE MODELS AS MEASURES OF PATIENT CARE**  
Holimon TD, Wurtzbacher JD. University of Tennessee College of Pharmacy. Department of Pharmacy Practice and Pharmacoeconomics, Memphis, TN, USA

**MM4**  
**RECONCILING DECISION MODEL SWITH THE REAL WORLD: THE COST-EFFECTIVENESS OF ERYTHROPOIETIN FOR ESRD-RELATED ANEMIA**  
Kauf T, Shih Y. UNC School of Pharmacy, Chapel Hill, NC, USA

**MM5**  
**COMPARING COMPUTERIZED OPTIONS IN PHARMACOECONOMICS: SPREADSHEETS, DECISION TREES AND EDUCATIONAL TOOLS: AN OPEN WORKSHOP FOR DEMONSTRATING SOFTWARE**  
McGhan WF. Philadelphia College of Pharmacy and Sciences, Philadelphia, PA, USA

**MM6**  
**DECISION ANALYSIS: WHAT IS ITS UTILITY FOR PHARMACOECONOMIC ANALYSIS?**  
Caro JJ, Migliaccio-Walle K. Caro Research, Boston, MA, USA

**MM7**  
**ISSUES IN DEVELOPING ECONOMIC MODELS FOR MANAGED CARE: THE CASE OF OSTEOPOROSIS PREVENTION**  
Funk Orsini P, Mullins CD, Wess SR, Preston KL. 1Parexel Int’l, Alexandria, VA, USA, 2University of Maryland, Baltimore, MD, USA

"DATA REGISTRIES AND DATA COLLECTION AND USE ISSUES"

**DA1**  
**USING MEDICATION HISTORY TO MEASURE INDICATION BIAS**  
Leader S, Mallick R. Praccon, Reston VA, USA

**DA2**  
**THE ROLE OF PATIENT REGISTRIES IN DISEASE MANAGEMENT AND OUTCOMES RESEARCH**  
Hartz SC, Huse DM. Medical Research International, Burlington, MA, USA

**DA3**  
**USING COMMUNITY PHARMACY TO CONDUCT OUTCOMES RESEARCH**  
Ungar WJ. Innovus Research Inc, Burlington, Ontario, Canada.

**DA4**  
**CONSTRUCTION OF A VALIDATED, NORMALIZED, GRANULAR ADMINISTRATIVE DATABASE AND ITS USE IN CLINICAL OUTCOMES IMPROVEMENT, CLINICAL RESEARCH AND PHARMACOECONOMIC RESEARCH**  
Morris S, Seltzer J, Bryant D, Premier, Inc. Charlotte, N C, 2Premier Research Worldwide, Phila, PA, USA

**DA5**  
**DISEASE STATE MANAGEMENT TRACKER: IMPLEMENTING, TRACKING, AND EVALUATING CLINICAL PATHWAYS AND OUTCOMES**  
Ambegaonkar Aj, Day D, Main J, Lubowski TJ, Yamaga C, VanVleet J. Clinical Pharmacy Outcomes Research, Pfizer Inc, New York, NY, USA

**DA6**  
**STRATEGIES FOR FORMULARY COMPARISONS IN THE MEDICAID MANAGED CARE ERA**  
Wurtzbacher JD, Holimon TD. University of Tennessee College of Pharmacy, Memphis, TN, USA

**DA7**  
**PROSPECTIVE, NATURALISTIC OUTCOMES MEASUREMENT: THE SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (SCAP)**  
Haley JC, Russo PA, Johnstone BM, Crown WH. 1Eli Lilly and Company, Indianapolis, IN, 2The MEDSTAT Group, W ashington, DC, USA

EVALUATING HEALTH OUTCOMES AND PHARMACOECONOMIC LITERATURE
Third Annual International Meeting
International Society for Pharmacoeconomics and Outcomes Research

Workshop Topics

“ECONOMIC ANALYSIS AND HEALTH CARE DECISION ISSUES”

DM1 INTERPRETING AND USING COST EFFECTIVENESS RESULTS
Bala, MV, Zarkin, GA, Research Triangle Institute, Research Triangle Park, NC, USA

DM2 DISSEMINATION OF PHARMACOECONOMIC RESULTS TO MANAGED CARE ORGANIZATIONS
Shreve JL, Pedlow KL, Marshall S, VanDenBos J, Milliman & Robertson, Inc., Denver, CO, USA

DM3 OUTCOMES RESEARCH IN MEDICATION USE: HCFA’S HEALTH CARE QUALITY IMPROVEMENT PROGRAM
Westrick E, Rhode Island Quality Partners, Providence, RI, USA.

“COSTING METHODOLOGY ISSUES”

CM1 ESTIMATING THE COSTS AND OUTCOMES FOR DIFFERENT DISEASE MANAGEMENT STRATEGIES: A CASE STUDY OF CYTOMEGALOVIRUS INFECTION AND DISEASE
Mauskopf J, Annemans L, Richter A, Chulay J, Maclaine G, Research Triangle Institute, RTP, NC; HEDM, Belgium; Glaxo Wellcome, RTP, NC, USA

CM2 CLINICAL INTERVENTION ASSESSMENT: IMPLEMENTATION OF DEFAULT VALUES FOR EXPEDITING THE CALCULATION OF COST SAVINGS AND COST AVOIDANCES
Mutnick A, Sterba K, Vrchoticky T. The University of Iowa Hospitals and Clinics, Iowa City, IA, USA

CM3 MULTIVARIABLE METHODS FOR MEASURING TREATMENT COSTS IN RANDOMIZED TRIALS
Polsky D, Glick H, University of Pennsylvania, Philadelphia, PA, USA

CM4 USE OF UB-92 AND MEDICARE COST REPORTS IN LARGE, MULTI-CENTER RANDOMIZED TRIAL: THE PURSUIT EXPERIENCE
Davidson-Ray L, Buell H, O’Neal B, McElwee N, Mark DB. 1Duke Clinical Research Institute, Durham, NC, USA; 2Schering-Plough, Corp., Kenilworth, NJ, USA

CM5 DISCOUNTING HEALTH BENEFITS IN PHARMACOECONOMIC ANALYSES: IS IT JUSTIFIED?
Caro JJ, Klittich WS, Caro Research, Boston, MA, USA

CM6 THE USE OF PATIENT SELF-REPORT TO COLLECT HEALTH CARE RESOURCE UTILIZATION DATA
Crawford B, Evans C, Charles River Associates, Boston, MA; Astra USA, Westborough, MA, USA

“UTILITIES METHODOLOGY ISSUES”

UT1 TRADE-OFF PREFERENCES FOR PHARMACEUTICAL DEVELOPMENT, MARKETING AND OUTCOMES ASSESSMENT
Johnson FR, Desvousges WH, Triangle Economic Research, Durham, NC, USA

UT2 PRACTICAL APPLICATIONS OF THE HEALTH UTILITIES INDEX

UT3 THE EuroQoL EQ-5D: AN OUTCOME MEASURE FOR USE IN CLINICAL AND ECONOMIC EVALUATION
Kind P, de Charro F, Centre for Health Economics, University of York, England; Centre for Health Policy, London, England; Erasmus University, Rotterdam, Netherlands

E X H I B I T S

Exhibitors will be presenting:

- pharmacoeconomic and outcomes assessment expertise and information
- healthcare database management
- pharmacoeconomic and outcomes assessment consulting and research services
- state-of-the-art software programs for pharmacoeconomic analyses
- pharmacoeconomic software applications for specific diseases
- economic and clinical data-capture software programs
ALL contributed poster presentations are available for viewing on Thursday, May 28 AND Friday, May 29

**Poster Topics**

“Economic and Outcomes Issues in Cardiovascular Disease”

FACTORS INFLUENCING THE DECISION TO TREAT SERUM LIPID DISORDERS BY DRUG THERAPY IN THE PRIMARY CARE VENUE
Yuan Y, Silbert G, Doyle J, Copeland K. IMS America, Plymouth Meeting, PA, USA

AN ANALYSIS OF THE ECONOMICS OF HYPERTENSION
West D, Corey R. University of Mississippi, Oxford, MS, USA, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

HOW DOES GENDER AFFECT PHARMACOTHERAPY TREATMENT DECISIONS FOR HYPERCHOLESTEROLEMIA/HYPERLIPIDEMIA
Copeland K, Yuan Y. IMS America, Plymouth Meeting, PA, USA

EMPIRICAL ANALYSIS OF THE COST-EFFICIENCY OF HMG-CoA REDUCTASE INHIBITORS
Foley J. L. Churchill Health Economics, Secaucus, NJ, USA

PHARMACEUTICAL COSTS OF PATIENT NON-ADHERENCE TO LIPID-LOWERING DRUG THERAPY

DEVELOPMENT OF A DECISION-ANALYTIC MODEL OF STROKE CARE IN USA AND EUROPE

ECONOMIC EVALUATION OF TO RAMISOIDE IN CONGESTIVE HEART FAILURE IN GERMANY
Spanheimer A, Goertz A. Kendle/gmi, Munich, Germany; Boehringer Mannheim, Mannheim, Germany

READINESS TO COMPLETE AND OUTCOMES OF ANTIHYPERTENSIVE THERAPY
Garfield FB, Wley C, Stafford J, Redding C, Caro JJ. Caro Research, Boston, MA, USA; University of Rhode Island, Kingston, RI, USA; Bristol-Myers Squibb/SanoPharma, Princeton, NJ, USA

STUDY OF HYPERTENSIVE PRESCRIBING PRACTICES
Schulman KA, Mehta SS, Gersh BJ, Schneider EC, Wilcox C. Clinical Economics Research Unit, Division of Cardiology, Institute for Health Care Research and Policy, Division of Nephrology and Hypertension at Georgetown University Medical Center, Washington, DC, USA

MEDICAL AND ECONOMIC OUTCOMES IN PATIENTS TREATED WITH DILTIAZEM OR DIGOXIN FOR ATRIAL FIBRILLATION: A DATA BASE ANALYSIS
Windschitl PA, Vlasses PH, Janowski L, University HealthSystem Consortium, Oak Brook, IL, USA

THE IMPACT OF UNSTABLE ANGINA ON THE USE OF MEDICAL RESOURCES IN ITALY
Maggiore AP, Schweiger C, Tavazzi L. On behalf of the EARISA Investigators: ANMCO Research Center, Florence, Italy

ONE YEAR CLINICAL AND ECONOMIC OUTCOMES OF PRIMARY CORONARY ANGIOPLASTY USING A NATIONAL DATABASE.
Akhras KS, Lowe LP, Arguelles LM, G. D. Searle & Co, Chicago, IL, USA

PREVALENCE AND COST OF HOSPITALIZATIONS DUE TO ANGINA IN THE UNITED STATES USING A NATIONAL DATABASE
Akhras KS, Zhao SZ, G. D. Searle & Co, Chicago, IL, USA

NONPARAMETRIC ANALYSIS OF COST EFFECTIVENESS RATIOS OF PRAVASTATIN IN PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE
Yuan Y, Hay J, LaPuerta P, Leary M. University of Southern California; Bristol-Myers Squibb Co., Princeton, NJ, USA; Pharmcon International, LLC, Old Lyme, CT, USA

STUDY OF PROTOCOL COSTS AND OUTCOMES ASSOCIATED WITH THE PHARMACOLOGICAL TREATMENT OF ARTERIAL DISEASE AND INTERMITTENT CLAUDICATION IN THE DEPARTMENT OF DEFENSE
Zachry W, Wison J, Lawson K, Koeller J. The University of Texas at Austin, Austin, TX, USA

SMOKING RELATED COSTS IN THE UNITED STATES
Chua W, Young TL, Lloyd KB, Sullivan SD. University of Washington Department of Pharmacy, Seattle, WA, USA; Glaxo Wellcome Inc., Research Triangle Park, NC, USA

LIPID THERAPY AND CARDIOVASCULAR DISEASE: HOW MANY AMERICANS SHOULD BE TREATED?
Yu W, Hay JW. University of Pittsburgh, School of Pharmacy, Pittsburgh, PA, USA, University of Southern California, School of Pharmacy, Los Angeles, CA, USA

THE IMPACT OF ACUTE RENAL FAILURE ON COST IN ELDERLY PATIENTS WITH CONGESTIVE HEART FAILURE
Chen Y-T, Bradford D, Wang Y, Seltzer S, Krumholz H. Yale University School of Medicine, New Haven, CT, USA; Connecticut Peer Review Organization, Middletown, CT, USA

LIPID THERAPY AND CARDIOVASCULAR DISEASE: HOW MANY AMERICANS SHOULD BE TREATED?
Yu W, Hay JW. University of Pittsburgh, School of Pharmacy, Pittsburgh, PA, USA, University of Southern California, School of Pharmacy, Los Angeles, CA, USA

THE IMPACT OF ACUTE RENAL FAILURE ON COST IN ELDERLY PATIENTS WITH CONGESTIVE HEART FAILURE
Chen Y-T, Bradford D, Wang Y, Seltzer S, Krumholz H. Yale University School of Medicine, New Haven, CT, USA; Connecticut Peer Review Organization, Middletown, CT, USA
INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH

THIRD ANNUAL INTERNATIONAL MEETING

POSTER TOPICS

EVALUATION OF THE COSTS OF HEART FAILURE IN BELGIUM
Annemans L1,2, Block P1, Van Rompay W1, Closon MC3, 1HEDM, Belgium; 2Vrije Universiteit Brussel, Belgium, 3Université Catholique Louvain, Belgium

CONVENIENCE IMPLICATIONS OF A SINGLE BOLUS THROMBOLYTIC
Banks JL1, Garfield FB1, LaPuerta P1, Spencer-Green G1, Caro JJ2, 1Caro Research, Boston, MA, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA

COST CONSEQUENCES OF ACUTE MYOCARDIAL INFARCTION IN DIABETIC PATIENTS — THE FIRST YEAR
O’Brien JA, Shomphe LA, Kavanagh PL, Caro JJ, 1Caro Research, Boston, MA, USA

“Economic and Outcomes Issues in GI Disorders, Diabetes, Asthma, and Other Disorders”

THE EFFECTS OF COMMUNITY-BASED PHARMACEUTICAL CARE SERVICES ON ASTHMA-RELATED QUALITY OF LIFE
Boyd BJ, Rascati, KL, Lawson, KA, 1The University of Texas at Austin College of Pharmacy, Austin, TX, USA

THE ECONOMIC IMPLICATIONS OF DECREASED PATIENT ADHERENCE TO CO-PRESCRIBED DICLOFENAC AND MISOPROSTOLUM (CoRx-D&M) RELATIVE TO A SINGLE TABLET FORMULATION OF DICLOFENAC MISOPROSTOLUM (STF-D/M).
Goldstein JL1, Stewart D2, Zabinski RA3, Larson LR4, 1University of Illinois Chicago, IL, USA; 2Brogan Inc., Toronto, Canada, 3GD Searle & Co, Skokie, IL, USA, 4ClinTrial Ovation, Highland Park, IL, USA

COST-UTILITY RELATIONSHIP OF TREATMENT OF DIABETIC FOOT LESION WITH HYPERBARIC OXYGEN THERAPY VERSUS STANDARD THERAPY
Kilburg A1, Rychlik R2, Rappenhöner B3, Institute of Empirical Health Economics, Odenthal, Germany

COST EFFECTIVENESS ANALYSIS OF SCREENING FOR TYPE II DIABETES MELLITUS IN NONPREGNANT ADULTS
Hui RL, Hay JW, School of Pharmacy, University of Southern California, Los Angeles, CA, USA

PREDICTING HOSPITALIZATION OF PATIENTS WITH DIABETES MELLITUS USING AN APPLICATION OF THE BAYESIAN DISCRIMINANT ANALYSIS
Bhattacharyya S, Procter & Gamble Pharmaceuticals, Cincinnati, OH, USA

A MANAGED CARE COST ANALYSIS OF THE TREATMENT OF PSORIASIS
Patterson HK, and Gillis SM1 SmithKline Beecham Pharmaceuticals, Collegeville, PA, USA

CONSEQUENCES OF HIGH HEMATOCRIT MAINTENANCE AMONG HEMODIALYSIS PATIENTS
Shih Y, Kauf TL1, UNC School of Pharmacy, Chapel Hill, NC, USA

OUTCOMES AND COST-BENEFIT OF INHALED CORTICOSTEROID THERAPY INTRODUCTION IN MEDICAID ENROLLED ASTHMATIC CHILDREN
Balkrishnan R, Norwood GJ, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

BAM BUTEROL IS A MORE COST-EFFECTIVE TREATMENT THAN SALMETEROL IN ASTHMA PATIENTS WITH NOCTURNAL SYMPTOMS
Crompton GK1, Brusasco V2, Eivindson A3, Jamieson AH4, Olsson H5, Svensson K6, Ståhl E7, 1Western General Hospital, Edinburgh, UK, 2Ospedale S Martino, Genova, Italy, 3Aust-Agder Sentralsethyhus, Arendal, Norway, 4Asta Clinical Research Unit, Edinburgh, UK, 5Astra Draco AB, Lund, Sweden

VETERANS’ SATISFACTION WITH H2-RECEPTOR ANTAGONIST (H2RA) DRUG CONVERSION
Lane K, Department of Veterans Affairs Medical Center, San Francisco, CA, USA

“Economic and Outcomes Issues in Hormone Replacement Therapy, Arthritis, and Osteoporosis”

EFFICIENT STRATEGIES FOR OSTEOPOROSISTESTING
Abbott TA1, Mucha LM1, Manfredonia D1, Schwartz E2, Berger M3, 1Merck & Co., Inc., West Point, PA, USA, 2Foundation for Osteoporosis Research & Education, Oakland, CA, USA
SF-12 OSTEOARTHRITIS-SPECIFIC HEALTH INDEX: DEVELOPMENT AND VALIDATION
Gandhi SK1, Salmon JW1, Zhao SZ2, Lambert BL1, Gore PI1, Conrad K1. 1University of Illinois at Chicago, Chicago, IL, USA; 2G. D. Searle, Skokie, IL, USA

PSYCHOMETRIC EVALUATION OF SF-12 IN OSTEOARTHRITIS CLINICAL TRIALS
Gandhi SK1, Salmon JW1, Zhao SZ2, Lambert BL1, Gore PI1, Conrad K1. 1University of Illinois at Chicago, Chicago, IL, USA; 2G. D. Searle, Skokie, IL, USA

THE RESPONSIVENESS OF DISEASE SPECIFIC AND GENERIC HEALTH MEASURES TO CHANGES IN THE SEVERITY OF RHEUMATOID ARTHRITIS AND TO TREATMENT
Kosinski M1, Ware JE1, Zhao S2, Dedhiya S2, 1The Health Assessment Lab, New England Medical Center, Boston, MA, USA; 2Searle, Skokie, IL, USA

THE RESPONSIVENESS OF DISEASE SPECIFIC AND GENERIC HEALTH MEASURES TO CHANGES IN THE SEVERITY OF OSTEOARTHRITIS
Zhao S1, Dedhiya S1, Kosinski M1, Ware JE1, 1Searle, Skokie, IL, USA; 2Health Assessment Lab, New England Medical Center, Boston, MA, USA

HEALTH CARE USE IN WOMEN AGE 45 AND OLDER
Hoerger TJ1, Eleazer KR1, Lindrooth RC1, West SL1, Hsfsfeldt R2, 1Research Triangle Institute, Research Triangle Park, NC, USA; 2Eli Lilly and Company, Indianapolis, IN, USA

THE DIRECT MEDICAL COST OF OSTEOPOROTIC FRACTURES
Martin BC, Kotzan JA, Reeves JH, College of Pharmacy, University of Georgia, Athens, GA, USA

CO ST-EFFECTIVENESS OF HORMONE THERAPY VERSUS CALCIUM THERAPY: AN OSTEOPOROSIS MARKOV MODEL
Keys PJ1, Touchette D2, 1Wayne State University College of Pharmacy and Allied Health Professions, Detroit, MI, USA; 2Detroit Medical Center Receiving Hospital, Detroit, MI, USA

USE OF CENTRALIZED PHARMACY RECORDS IN A MANAGED CARE ORGANIZATION TO DETERMINE EFFECT OF EDUCATIONAL MATERIAL ON HORMONE REPLACEMENT THERAPY PATIENT COMPLIANCE
Chen Y1, McDougit J1, Wolke O1, Sidorov J1, 1MEDEX Clinical Trials Services, Ardmore, PA, USA, 2Penn State Geisinger Health System, Danville, PA, USA

QUALITY OF LIFE AND PHARMACOECONOMIC ASPECTS OF HORMONE REPLACEMENT THERAPY IN POSTMENOPAUSAL WOMEN: A CANADIAN RANDOMIZED TRIAL
Haider S1, Benhaddad A2, Rosner A1, Ryan N1, Hux M1, 1Abt Associates Clinical Trials, Cambridge, MI, USA; 2Schering Canada Inc., Pointe-Claire, QC, Canada

DETERMINING MINIMALLY IMPORTANT CHANGES (MIC) IN RHEUMATOID ARTHRITIS (RA) FUNCTIONAL STATUS
Bagchi I1, Gillis SM1, Watrous ML1, 1University of Iowa, Iowa City, IA, USA; 2SmithKline Beecham Pharmaceuticals, Collegeville, PA, USA

“Economic and Outcomes Issues of Immune and Infections Diseases and Cancer”
MARKOV CHAIN ESTIMATION OF LIFE EXPECTANCY OF HIV-INFECTED PATIENTS: COMPARISON OF TWO TREATMENT ALTERNATIVES
Bhattacharyya SK1, Langley PC1, Draugalis JR1, Cox ER1, 1Procter & Gamble Pharmaceuticals, Cincinnati, OH, USA; 2University of Colorado Health Sciences Center, Denver, CO, USA; 3The University of Arizona, Tucson, AZ, USA; 4The University of Arizona, Tucson, AZ, USA

SOCIO-ECONOMIC RELEVANCE OF INPATIENT TREATMENT OF INTRA-ABDOMINAL INFECTION WITH TAZOBACTAM / PIPERACILLIN 0.5 g / 4.0 g IN COMPARISON WITH IMIPENEM / CILASTATIN
Domínguez-Gil A1, Pérez M1, Santos L1, Sanz A1, Rubio C1, 1Hospital Universitario de Salamanca, Salamanca, Spain; 2University of Salamanca, Salamanca, Spain; 3Hospital Universitario de Salamanca, Salamanca, Spain

USING A PNEUMONIA SPECIFIC SEVERITY OF ILLNESS MODEL IN ASSESSING VARIATION IN HOSPITAL LENGTH OF STAY FOR COMMUNITY ACQUIRED PNEUMONIA PATIENTS
Tan, H, Koeller, J, The University of Texas at Austin and Health Science Center in San Antonio, TX, USA

CLINICAL & ECONOMIC BENEFITS OF AN INFECTIOUS DISEASE APPROVAL PROGRAM.
Kinky DE, Fishman NO, Morgan AS, Gibson GA. University of Pennsylvania Medical Center, Philadelphia, PA, USA
Third Annual International Meeting
International Society for Pharmacoeconomics and Outcomes Research

Poster Topics

THE CLINICAL AND ECONOMIC BENEFIT OF AN INFECTIOUS APPROVAL PROGRAM
Kinky DE, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

THE INFLUENCE OF CASE MIX ON HOSPITALISATION FOR LOWER RESPIRATORY TRACT INFECTION
Peter Davey, McMahon AD, White G, Morris AM, MacDonald TM, MEMO, Dundee, Scotland, UK

A HEALTH ECONOMIC EVALUATION OF PACLITAXEL AND CARBOPLATIN VERSUS VINORELBINE AND CISPLATIN COMBINATION CHEMOTHERAPY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
Sinha N, Hainsworth J, Einaron TR, Doyle JJ, Arikian SR, Lappas PT, Center for Health Outcomes and Economics, A Division of Bristol-Myers Squibb Company, East Brunswick, NJ, USA, Sarah Cannon Cancer Center, Nashville, TN, USA, University of Toronto, Toronto, Canada

"Methods, Surveys, Data Collection, and Use, and Other Issues"

INFORMATION TECHNOLOGY IN A LARGE MULTI-SITE OUTCOMES STUDY
Morlock R, Ward R, Nerenz D, Feng J, Sadlocha K, Henry Ford Health System, Detroit, MI, USA, Oceania Inc., Palo Alto, CA, USA

THE EFFECT OF THE LOUISIANA MEDICAID LOCK-IN ON PRESCRIPTION DRUG UTILIZATION AND EXPENDITURES
Blake SG, Feldhaus JF, Hunter TS, Rappaport H, Holt G, Medon PJ, Northeast Louisiana University, School of Pharmacy, Monroe, LA, USA

USE OF ADMINISTRATIVE DATA TO CREATE DISEASE-SPECIFIC DATASETS FOR USE IN HEALTH ECONOMIC STUDIES
Beck P, Downey W, Osei W, Baker M, Saskatchewan Health, Regina, Canada

OUTCOMES RESEARCH INTERESTS OF A COMMUNITY PHARMACIST RESEARCH NETWORK
Wade WE, Spruill JW, Taylor AT, College of Pharmacy, The University of Georgia, Athens, GA, USA

PRESCRIPTION MEDICATION USE IN OLDER AMERICANS
Mehta SS, Rathore SS, Boyko EJ, Schulman KA, Clinical Economics Research Unit, Department of Medicine, Georgetown University Medical Center, Washington, DC, USA

CHRONIC CARE COSTS OF NEW MEDICARE HMO ENROLLEES: IMPLICATIONS FOR DISEASE MANAGEMENT
Grannemann TW, Boxford, MA, USA

THE VALUE OF MEDICINES: IS THERE ENOUGH ECONOMIC EVIDENCE?
Constenla D, Munro V, Hutton J, MEDTAP International Inc., London, UK

PRENATAL CARE AND BIRTH WEIGHT IN THE UNITED STATES
Weiwei F, Merck-Medco Managed Care, LLC, Montvale, NJ, USA

EVALUATION OF A PATHWAY FOR PROVIDING PHARMACEUTICAL CARE
Burgess S, Perri M, Department of Clinical and Administrative Sciences, University of Georgia, Athens, GA, USA

THE DEVELOPMENT OF A PATIENT OUTCOMES SOFTWARE FOR UROLOGISTS: CAPSURE®
Flanders S, Henning JM, Roth J, Stier DM, Grossfeld GD, Carroll PR, TAP Holdings Inc., Deerfield, IL, USA

APPLICATION OF PHARMACOECONOMICS AND OUTCOMES RESEARCH IN FORMULARY DECISION-MAKING
Sarpong DF, Xavier University, College of Pharmacy, New Orleans, LA, USA

VOX POPULI: STATED PREFERENCES FOR PHARMACEUTICAL INNOVATIONS
Bingham MF, Johnson FR, Bell L, Triangle Economic Research, Durham, NC, USA, Independent Consultant

AN UNBIASED METHOD OF PHARMACEUTICAL COST ANALYSIS
Nichol G, Wells G, Pham B, University of Ottawa, Ottawa, Canada

IMPLICATIONS OF PREVENTING DISEASE ON LIFE YEARS GAINED (LYG)
Caro JJ, Kiltich WS, Johnson FD, Caro Research, Boston, MA, USA, Bristol-Myers Squibb, Princeton, NJ, USA

SURVEILLANCE OF A NEW DRUG IN THE UNITED KINGDOM (U.K.)
Hartz SC, West S, Bunten E, Medical Research International, Burlington, MA, USA

"Economic and Outcomes Issues in Mental Health and Neurologic Disorders"

THE ECONOMIC BURDEN OF SCHIZOPHRENIA: ACUTE GENERAL HOSPITAL COST
O'Brien JA, Shomphe LA, Pietrusewicz MJ, Caro JJ, Caro Research, Concord, MA, USA

ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE DURING TREATMENT OF OPIOID DEPENDENCE USING THE SHORT FORM - 36
Raisch DW, Garnand DA, Jones MS, Bette A, Ling W, VA Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, USA, LA Addiction Treatment Research Center, Los Angeles, CA, USA
EVALUATION OF HUMANISTIC OUTCOMES FOR PATIENTS ON SELECTIVE SEROTONIN REUPTAKE INHIBITORS
Sansgiry SS, Burgoyne DS, Busby CJ, RxAmerica LLC, Salt Lake City, UT, USA; Eli Lilly and Company, Sandy, UT, USA

QUALITY OF LIFE AND ADVERSE REACTIONS IN DEPRESSED PATIENTS RECEIVING ANTIDEPRESSANT DRUGS
Taylor AT, Spruill WJ, Longe RL, Wade WE, Ahmed A. University of Georgia, Athens, GA, USA

THE COST OF TREATING SCHIZOPHRENIA IN THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM
McCombs JS, Nichol MB, Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA

ECONOMIC OUTCOMES OF ANTIDEPRESSANT USE IN A MANAGED CARE ORGANIZATION
White TJ, Nichol MB, USC School of Pharmacy, Department of Pharmaceutical Economics and Policy, LA, CA, USA

A GENERAL MODEL OF THE EFFECTS OF ALTERNATIVE SEDATIVE-HYPNOTIC AGENTS ON THE COSTS OF MOTOR VEHICLE ACCIDENTS
Menzin J, Lang K, Friedman M, Boston Health Economics, Inc., Billerica, MA, USA

DURATION OF CONTINUOUS USTHERAPY BETWEEN ATYPICAL AND TYPICAL ANTIPSYCHOTICS
Li Z, Hutchins DS, Johnstone BM, Tunis SL, Coleman TR, Gevirtz F, PCS Health Systems Inc., Scottsdale, AZ, USA; Eli Lilly and Company, Indianapolis, IN, USA

MONTH-TO-MONTH ADHERENCE WITH ANTIPSYCHOTIC PHARMACOTHERAPY: A COMPARISON BETWEEN ATYPICAL AND TYPICAL ANTIPSYCHOTICS
Li Z, Hutchins DS, Johnstone BM, Tunis SL, Coleman TR, Gevirtz F, PCS Health Systems Inc., Scottsdale, AZ, USA; Eli Lilly and Company, Indianapolis, IN, USA

SELECTIVE SEROTONIN REUPTAKE INHIBITOR UTILIZATION PATTERNS: CONSISTENCY ACROSS RESEARCH DESIGNS
Hutchins DS, Klein EG, Signa WF, Young CH, Gregor KJ, PCS Health Systems Inc., Scottsdale, AZ, USA; Eli Lilly and Company, Indianapolis, IN, USA

MONTH-TO-MONTH ADHERENCE WITH ANTIPSYCHOTIC PHARMACOTHERAPY: A COMPARISON BETWEEN ATYPICAL AND TYPICAL ANTIPSYCHOTICS
Li Z, Hutchins DS, Johnstone BM, Tunis SL, Coleman TR, Gevirtz F, PCS Health Systems Inc., Scottsdale, AZ, USA; Eli Lilly and Company, Indianapolis, IN, USA

UTILIZATION REVIEW OF SSRITHERAPY AT A MENTAL HEALTH MANAGED CARE ORGANIZATION
Conner TM, Rascati KL, Crawford KM. The University of Texas at Austin, Austin, TX, USA

TEXAS MEDICATION ALGORITHM PROJECT: FEASIBILITY STUDY OF IMPLEMENTING MEDICATION ALGORITHMS IN THE PUBLIC MENTAL HEALTH SECTOR
Crismon ML, Rush AJ, Toprac MG, Shon S, Biggs MM, Shores-Wilson K, Mason M. The University of Texas System and Texas Department of Mental Health and Mental Retardation, Austin, TX, USA

DEVELOPING A TASK-BASED STRATEGIC TO MEASURE MIGRAINE RELATION TO PRODUCTIVITY
Lee TA, Ramsey SD, Neil NJ, Patrick DL, Klastorin TD, Stergachis A, Sullivan SD, University of Washington, School of Pharmacy, Medicine, Public Health and Community Medicine, Business Administration, Seattle, WA, USA

SCIZOPHRENIA MANAGEMENT: DOES MANAGED CARE INFLUENCE LENGTH OF STAY IN U.S. HOSPITALS?
O'Brien JA, Pietrusewicz MJ, Pierce D, Caro JJ, Research, Boston, MA, USA

DEVELOPMENT OF A SELF-ADMINISTERED OUTCOME MEASURE FOR USE IN AN OUTPATIENT POPULATION OF INDIVIDUALS WITH SCHIZOPHRENIA
Judith Barr, Schumacher GE, Mason EJ, Ohman SM, Hanson A, Northeastern University and Massachusetts Division of Medical Assistance.

A HEALTH POLICY ANALYSIS OF PHARMACOTHERAPY FOR MAJOR DEPRESSIVE DISORDER IN EUROPE AND THE AMERICAS
Arikan SR, Einaron TR, Cascio JP, Doyle JJ, The Analytica Group, Ltd., Scarsdale, NY, Columbia School of Public Health, New York, NY, USA, Faculty of Pharmacy, The University of Toronto, Ontario, Canada

UTILIZATION PATTERN SO FANTIDEPRESSANT MEDICATIONS IN A PATIENT POPULATION SERVED BY A PRIMARY CARE MEDICAL GROUP
Venturini F, Sung J, Nichol MB, Selner J, University of Southern California, School of Pharmacy, Department of Pharmaceutical Economics & Policy, Los Angeles, CA, USA; Eli Lilly & Co., Indianapolis, IN, USA

Accreditation

Continuing education credit for pharmacists will be provided by Butler University.

Butler University designates this continuing pharmaceutical education activity for up to 17 hours (1.7 CEUs). Rutgers, Butler University is approved by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

To receive continuing education credit, indicate on the Meeting Registration Form that CE accreditation is requested. Complete the CE Credit Form available at the Meeting Registration Desk and submit to the ISPOR Meeting Staff Office for validation. The continuing education processing fee is $30.
ISPOR PERSONNEL PLACEMENT CENTER

The International Society for Pharmacoeconomics and Outcomes Research provides an opportunity for individuals seeking positions and employers with available positions to arrange for personal interviews during this meeting. This is a service provided to ISPOR members to foster career growth and the development of its members.

APPLICANT INSTRUCTIONS:
1. Bring at least 10 copies of your resume to the Third Annual International Meeting.
2. Leave 2 copies of your resume at the ISPOR Personnel Placement Center and indicate the positions for which you are interested.
3. Indicate the time you are available for interviews. Note: The place for the interview will be noted on the position sign-up sheet.
This service is FREE to ISPOR members. For non-members, the fee is $75 ($25 for full-time students).

POSITION LISTING INSTRUCTIONS:
The ISPOR Personnel Placement Center provides the following services for employers with positions in pharmacoeconomics and outcomes assessment:

• Publication of the positions in the Third Annual International Meeting Program (if received by May 1, 1998)
• Coordination of the interview schedule
• A private room for each interview

Procedure:
1. Send to the address below the position description(s) with cover letter indicating (a) the employer contact person; (b) their office telephone number; and (c) the contact person who will be attending the ISPOR Annual Meeting and will be interviewing candidates. POSITION DESCRIPTION(S) MUST BE RECEIVED BY MAY 1, 1998.
2. After May 1, 1998, bring your position description(s) to the ISPOR Personnel Placement Center at the ISPOR Second Annual International Meeting.
3. The interviewer will receive the interview schedule and assigned private room at the ISPOR Personnel Placement Center.
4. The address to send position description(s) and cover letter is: ISPOR Personnel Placement Center, ISPOR, 20 Nassau Street, Suite 307, Princeton, NJ 08542
The fee for this service is $1000.

The Career Development/Personnel Placement Center and the International Society for Pharmacoeconomics and Outcomes Research subscribe to the principle of Equal Employment Opportunity. Employers certify by participation that their employees receive fair and equal treatment, regardless of race, age, sex, religion, nation origin, or disability, in the hiring, placement, promotion, transfer, pay rate, and termination of employment.

ASK FOR AN ISPOR PERSONNEL PLACEMENT FOLDER FOR JOB POSITIONS WHEN YOU REGISTER
REGISTRATION FORM

Name ________________________________________________________________________________________

Position/Title: _______________________________________________________________________________

Institution Name: _____________________________________________________________________________

Mailing Address: 

Suite/Room: __________________________________________________________________________________

Street: _______________________________________________________________________________________

City: _________________________________________________________________________________________

State Zip: _____________________________ Country: _______________________________________

Work Phone: _____________________________ Fax Number: _______________________________________

E-mail Address: _______________________________________________________________________________

MEETING REGISTRATION: (Check appropriate box)

- US $395  
- US $470

- US $495  
- US $570

- US $595  
- US $670

- US $75  
- US $100

- US $125  
- US $150

- US $175  
- US $200

- US $30  
- US $30

- US $125  
- US $200

- US $250  
- US $400

Short Courses (4 hours) Before May 1, 1998

- US $125 [x # of courses]  
- US $200 [x # of courses]

Short Courses (4 hours) After May 1, 1998

- US $250 [x # of courses]  
- US $400 [x # of courses]

Total Registration Fee: $__________ $__________

Please enclose a check or money order payable in US dollars to: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and send to the address given below or please charge to: ☐ VISA ☐ MASTERCARD ☐ American Express

Account Name: ____________________________ Expiration Date: _________________ Account Number: ____________________________

Authorized Signature: _______________________________________________________________________

Payment must be made in US Dollars. Payment may be made by check, money order or travelers check. VISA, MASTERCARD or American Express are also accepted. Signature, account number, and expiration date must be included. Non-US checks must be written on banks with a US counterpart. Phone charges will NOT be accepted. If payment is being made by your company, please make sure your name is indicated on the check stub or correspondence. Students must send proof of current full-time enrollment.

SEND (OR FAX, IF USING CREDIT CARD) REGISTRATION FORM TO:

International Society for Pharmacoeconomics and Outcomes Research

20 Nassau Street Suite 307 Princeton, New Jersey 08542

Phone: 609-252-1305 • Fax: 609-252-1306 • email: econhealth@aol.com

Cancellation fee before April 27, 1998 is US $100. No refunds will be given after April 27, 1998.

Hotel: Philadelphia Marriott • 1201 Market Street • Philadelphia, PA 19107 • 800-320-5744 or 215-625-2900 • Fax: 215-625-6101

$161 Single • $177 Double • Deadline April 30, 1998 • Ask for special ISPOR Group Block Rate
The Philadelphia Marriott is the official hotel for the ISPOR Third Annual International Meeting and is located in downtown Philadelphia. Meeting attendees will receive special hotel rates of:

- $161 single occupancy
- $177 double occupancy
- $20 for additional persons

To make your reservations:

- call the Marriott Reservation Department (1-800-320-5744 or 215-625-2900) and ask for the special ISPOR group block rate.
- or Complete the hotel registration form below and send or fax to:
  Reservation Department • Philadelphia Marriott • 1201 Market Street • Philadelphia, PA 19107 • Fax# 215-625-6101

RESERVATIONS BY ATTENDEES MUST BE RECEIVED ON OR BEFORE APRIL 27, 1998.

All reservation requests will require a guarantee of payment for the first night. This guarantee of payment may be made by enclosing a check, money order or the entire number of one of the following credit cards: American Express, Diners Club, Visa, Master Card, Discover or Carte Blanche. The advance deposit is refundable only if the reservation is canceled at least 48 hours prior to arrival date. Reservations received after April 27, 1998 will be confirmed on a space available basis only, and may not be available at the special ISPOR group rate. Guaranteed reservations are held without occupancy for one night only and not for entire length of stay requested. Room rates do not include tax, which is currently 13%. Room tax is subject to change without notice. Check-in time is 4:00 PM and check-out time is 12:00 noon. Valet parking is available at $20 per day.

DO NOT SEND HOTEL RESERVATION FORM TO ISPOR

Please print
Name: _____________________________________________________________________________________________________________________

Company Name: ____________________________________________________________________________________________________________

Address: __________________________________________________________________________________________________________________

City: _____________________________________________________________________________________________________________________

State/Zip: _____________________________________________ Country: ____________________________________________________________

Phone: ___________________________________________________________________________________________________________________

What major credit card will be used for payment upon checkout?
Card name: ____________________________________________ Card Number:_______________________________________________________

Signature: _____________________________________________ Exp. Date: __________________________________________________________

Above card will also be used for guarantee for late arrival

☐ Check here if confirmation notice is required.  Arrival Date: __________ Arrival Time: ______  ☐ AM  Departure Date: _______

Requested Room Type:
☐ Smoking  ☐ N on-smoking  ☐ W heelchair Accessible  ☐ 1 King Bed  ☐ 2 Double Beds  ☐ N o preference :

Student Housing

Student Housing will be offered to full-time students who would like to share the cost of a hotel room with another student. For more information, please contact Jennifer Olson, ISPOR Director of Meeting and Conventions, at 609-252-1305.
Exhibits

Exhibitors will be presenting:
• pharmacoeconomic and outcomes assessment expertise and information
• healthcare database information
• pharmacoeconomic and outcomes assessment consulting and research services
• state-of-the-art software programs for pharmacoeconomic analyses
• pharmacoeconomic software applications for specific diseases
• economic and clinical data-capture software programs

Exhibit hours are:
Thursday, May 28, 1998  10:00 AM to 6:00 PM
   Exhibitors Open House  6:00 PM to 7:00 PM
Friday, May 29, 1998    7:00 AM to 3:00 PM

If you are interested in exhibiting at the ISPOR Third Annual International Meeting, please contact Jennifer Olson, ISPOR Director of Meetings & Conventions at 609-252-1305.

EXHIBITORS (to date):
Abt Associates
Adis International
Assist Technologies
Applied Healthcare Informatics
Blackwell Science
Clinical Therapeutics®
ClinTrials Ovation
IMS America
The MEDSTAT Group
OHE-IFPMA Database Ltd.
PAREXEL / S & FA
Stuart Disease Management Services (SDMS)
TreeAge Software
TJU, Office of Health Policy & Clinical Outcomes

EXHIBITORS (to date):
Abt Associates
Adis International
Assist Technologies
Applied Healthcare Informatics
Blackwell Science
Clinical Therapeutics®
ClinTrials Ovation
IMS America
The MEDSTAT Group
OHE-IFPMA Database Ltd.
PAREXEL / S & FA
Stuart Disease Management Services (SDMS)
TreeAge Software
TJU, Office of Health Policy & Clinical Outcomes